Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 29, 2021Genome MedicineOpen Access

Actionability of commercial laboratory sequencing panels for newborn screening and the importance of transparency for parental decision-making

View Full Paper
Ask AI
Bookmark
Share

Authors

DDDaniela M. DeCristoLMLaura V. MilkoJOJulianne M. O’Daniel

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

DeCristo et al. (2021) studied this question.

synapsesocial.com/papers/6ab9de26eee98bef42034b0ehttps://doi.org/10.1186/s13073-021-00867-1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Citizens’ Values Regarding Research With Stored Samples From Newborn Screening in Canada2012 · 47 citations
  2. 2Revisting wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years2008 · 917 citations
  3. 3Physiologic diagnosis of congenital heart disease in cyanotic neonates2019 · 32 citations
  4. 4Newborn Screening: Toward a Uniform Screening Panel and System—Executive Summary2006 · 503 citations